Payments in the Event of Sublicense Sample Clauses

Payments in the Event of Sublicense. In the event BGM enters into a Sublicense with a Third Party granting to the Sublicensee a sublicense under any rights granted to BGM pursuant to a License of any Subject IP hereunder (the “Sublicensed Rights”), BGM’s obligation to pay royalties under Section 2.02(a) above with respect to the Sublicensed Rights subject to the Sublicense shall terminate and, in lieu thereof, BGM shall pay to ACSB such percentage of all Sublicensing Income received by BGM from the Third Party Sublicensee with respect to the Sublicensed Rights subject to the Sublicense, and upon such additional terms and conditions, as shall be set forth in the Licensing Addendum in which the applicable Subject IP is identified. subject. To the extent the Sublicensed Rights do not include all of the rights granted to BGM with respect to the applicable Subject IP, ACSB shall continue to be entitled to royalties under Section 2.02(a) with respect to those rights retained by BGM or its Affiliates and not subject to the Sublicense. Amounts payable to ACSB based on Sublicensing Income shall be payable for the same term as royalties would have been payable pursuant to Section 2.02(a)(ii)1) above.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Payments in the Event of Sublicense. In the event INDEVUS enters into one or more sublicense agreement(s) with one or more Third Party or Third Parties under Section 2.3 of this Agreement, the respective percentages of royalties set forth in Section 5.3.1 would no longer be applicable to the Net Sales in the country or countries covered by the sublicense agreement(s) and, in lieu thereof, AVENTIS would receive the following respective percentages of the total Sublicense Royalty Payments for the concerned country(ies): • [*] percent ([*]%) if the sublicense agreement is entered into [*]; • [*] percent ([*]%) if the sublicense agreement is entered into [*]; and *CONFIDENTIAL TREATMENT REQUESTED • [*] percent ([*]%) if the sublicense agreement is entered into [*]. In order to calculate the amounts due to AVENTIS under this Section 5.3.2, it is understood that (i) any payment to INDEVUS by a sublicensee that is triggered by Net Sales (such as but not limited to fees) shall be considered Sublicense Royalty Payments; and (ii) if no royalties or a lower royalty percentage is paid by INDEVUS’ Sublicensee in consideration of an increased margin received by INDEVUS on Compound or Product supply or of higher milestones payments, such excess payments shall be considered Sublicense Royalty Payments.
Sample 1
Payments in the Event of Sublicense. In the event INDEVUS enters into a sublicense with a Third Party or Third Parties under Section 2.3 of this Agreement, then the following shall be applicable as of the effective date of the sublicense:
Sample 1
Payments in the Event of Sublicense. (i) In the event INTERNEURON enters into a sublicense with a Third Party or Third Parties under Section 2.3 of this Agreement, then in lieu of INTERNEURON paying URIACH the royalty payments set forth in Section 5.3.1 above, INTERNEURON shall pay URIACH [*] of royalty payments received by INTERNEURON ("INTERNEURON Royalties") which shall at all times be based on net sales of Product by Sublicensee(s) (such net sales to be defined in any sublicense agreement in terms materially consistent with the definition of Net Sales contained in this Agreement). If INTERNEURON enters into a sublicense with a Third Party under Section 2.3 of this Agreement for the United States prior to completion of the Phase 2 Clinical Trial, INTERNEURON shall pay URIACH [*] of INTERNEURON Royalties received from such Sublicensee. Payments shall be required under this Section 5.3.2(i) for so long as INTERNEURON is receiving INTERNEURON Royalties. * Confidential Treatment Requested
Sample 1
Payments in the Event of Sublicense. In the event MediciNova enters into one or more sublicense agreement(s) with one or more Third Party or Third Parties under Section 2.02 of this Agreement, the respective percentages of royalties set forth in Section 5.02 would no longer be applicable to the Net Sales in the country or countries covered by the sublicense agreement(s) and, in lieu thereof, MediciNova shall pay to Kissei the following respective percentages of the total Sublicense Royalty Payments for the concerned country(ies):
Sample 1
Payments in the Event of Sublicense. (i) In the event MEDICINOVA enters into a sublicense with a Third Party or Third Parties under Section 2.4 of this Agreement of any rights licensed to MEDICINOVA by ANGIOGENE under Section 2.1 of this Agreement, then in lieu of MEDICINOVA paying ANGIOGENE the milestone payments set forth in Section 5.2 above and the royalty payments set forth in Section 5.3.1 above, MEDICINOVA shall pay ANGIOGENE the following applicable percentages of Sublicense Consideration received by MEDICINOVA from such sublicensee(s):
Sample 1
Payments in the Event of Sublicense. In the event INDEVUS enters into a Sublicense with a Third Party granting to the Sublicensee a sublicense under any or all of the rights granted to INDEVUS under Section 2.1 above in any or all of the countries in the Territory (the “Sublicensed Rights”), INDEVUS’s obligation to pay XXXXXXXX royalties under Section 5.4 (a) above with respect to the Sublicensed Rights subject to the Sublicense shall terminate and, in lieu thereof, INDEVUS shall pay to XXXXXXXX [*] percent ([*]%) of all Sublicense Royalty Payments received by INDEVUS from the Third Party Sublicensee with respect to the Sublicensed Rights subject to the Sublicense, subject to the provisions of Sections 5.4 (e) and (g) below. To the extent the Sublicensed Rights do not include all of the rights granted to INDEVUS under Section 2.1 above, XXXXXXXX shall continue to be entitled to royalties under Section 5.4 (a) with respect to those rights retained by INDEVUS or its Affiliates and not subject to the Sublicense. Except as required under Section 5.4 (g) hereof, *CONFIDENTIAL TREATMENT REQUESTED no royalties shall be payable by INDEVUS with respect to net sales by a Sublicensee. Amounts payable to XXXXXXXX based on Sublicense Royalty Payments shall be payable for the same term as royalties would have been payable pursuant to Section 5.4 (a) (ii) above.
Sample 1
AutoNDA by SimpleDocs
Payments in the Event of Sublicense. In the event PATHOGENICS ----------------------------------- enters into a sublicense with a Third Party or Third Parties under Section 2.3 of this Agreement and ceases the manufacture, use, and sale of Product, then as of the effective date of the sublicense PATHOGENICS' obligation to pay ALPHA RESEARCH any royalties or milestone payments under Section 5.1.1 above shall terminate and, in lieu thereof, ALPHA RESEARCH shall be entitled to twenty percent (20%) of Sublicense Payments received by PATHOGENICS.
Sample 1
Payments in the Event of Sublicense. In the event MEDICINOVA enters into a sublicense with a Third Party or Third Parties under Section 2.3 of this Agreement of any rights licensed to MEDICINOVA by LICENSORS under Section 2.1 of this Agreement, then in lieu of MEDICINOVA paying to RIKEN the royalty payments set forth in Section 5.3.1 above, MEDICINOVA shall pay to RIKEN, on behalf of RIKEN and MIKOSHIBA, [**] of royalties received by MEDICINOVA from such sublicensee(s) (the “Sublicense Royalty Payments”). Payments shall be required under Section 5.3.2 for the same period set forth in Section 5.3.1(b) hereof.
Sample 1

Related to Payments in the Event of Sublicense

  • Grant of Sublicense Subject to the terms and conditions of this Agreement, Adviser hereby grants to the Trust a non-transferable sublicense to use the Index (and associated data and information) listed on Exhibit A in the manner set forth in, and subject to the terms of, the License Agreement.

  • Survival of Sublicenses Upon termination of this Agreement for any reason, any sublicense granted by Unity hereunder to a Third Party Sublicensee shall survive, provided that such Third Party Sublicensee continues to pay to Ascentage the milestones and royalties that would have been due to Ascentage under this Agreement based on such Third Party Sublicensee’s activities had this Agreement not terminated. For clarity, in the event that a Third Party Sublicensee fails to pay to Ascentage the applicable milestones and royalties due to Ascentage based on such Third Party Sublicensee’s activities, Ascentage shall be entitled to terminate such surviving sublicense by providing such Third Party Sublicensee written notice of termination, which notice shall take effect [***] ([***]) days after it is received by such Third Party Sublicensee unless such Third Party Sublicensee has cured any such breach or default prior to the expiration of the [***] ([***]) day period.

  • Effect of Termination on Sublicenses Any sublicenses granted by Company under this Agreement shall provide for termination or assignment to Hospital of Company’s interest therein, at the option of Hospital, upon termination of this Agreement or upon termination of any license hereunder under which such sublicense has been granted.

  • Termination of License Upon the expiration or earlier termination of this Agreement (or of a Licensee’s rights to use the Citi Marks hereunder, in which case the following provisions of this Section 6.02 shall apply only with respect to such Licensee):

  • Termination of License Agreement Without limiting the generality of the foregoing, in the event that the License Agreement is terminated in accordance with its terms, this Agreement, including without limitation any Purchase Order(s) or Project Work Orders then-in-effect, shall automatically terminate in its entirety as of the effective date of termination of the License Agreement.

  • Exclusive License Grant Subject to the terms and conditions of this Agreement, Licensee hereby grants to Takeda an exclusive, sublicensable (subject to Section 3.3 (Sublicensing)), royalty-bearing right and license under the Licensee Technology and Licensee’s interest in the Joint Technology to Exploit the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Field in the Takeda Territory.

  • Exclusive License Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor, upon the terms and conditions herein specified, a sole and exclusive license under the Licensed Patent Rights in the Territory, and in the Field of Use to develop, make, have made, import, have imported, use, offer to sell, sell and otherwise commercialize Licensed Product(s).

  • Payment of Sales, Use or Similar Taxes All sales, use, transfer, intangible, recordation, documentary stamp or similar Taxes or charges, of any nature whatsoever, applicable to, or resulting from, the transactions contemplated by this Agreement shall be borne by the Sellers.

  • Termination of Licenses In the event of a termination of this Agreement by COMPANY pursuant to Article 9.2. 9.3 or 9.4 or by SELEXIS pursuant to Article 9.2 or 9.3, all and any rights and licenses granted under this Agreement shall terminate upon termination of this Agreement, except for the licenses which have become perpetual pursuant to Article 3.1.3.

  • Certain Actions Permitted Notwithstanding anything herein to the contrary, (a) each Agent may make such demands or file such claims in respect of the Senior Priority Obligations or Junior Priority Obligations, as applicable, owed to such Agent and the Creditors represented thereby as are necessary to prevent the waiver or bar of such claims under applicable statutes of limitations or other statutes, court orders, or rules of procedure at any time, (b) in any Insolvency Proceeding commenced by or against the Borrower or any other Credit Party, the Junior Priority Agent or the Junior Priority Creditors may file a proof of claim or statement of interest with respect to the Junior Priority Obligations, (c) the Junior Priority Creditors shall be entitled to file any necessary responsive or defensive pleadings in opposition to any motion, claim, adversary proceeding or other pleading made by any person objecting to or otherwise seeking the disallowance of the claims of the Junior Priority Creditors, including without limitation any claims secured by the Collateral, if any, in each case if not otherwise in contravention of the terms of this Agreement, (d) the Junior Priority Creditors shall be entitled to file any pleadings, objections, motions or agreements which assert rights or interests available to unsecured creditors of the Credit Parties arising under either the Bankruptcy Law or applicable non-bankruptcy law, in each case if not otherwise in contravention of the terms of this Agreement, (e) the Junior Priority Creditors shall be entitled to file any proof of claim and other filings and make any arguments and motions in order to preserve or protect its Liens on the Collateral that are, in each case, not otherwise in contravention of the terms of this Agreement, with respect to the Junior Priority Obligations and the Collateral and (f) the Junior Priority Agent or any Junior Priority Creditor may exercise any of its rights or remedies with respect to the Collateral after the termination of the Standstill Period to the extent permitted by Section 2.3 above.

Time is Money Join Law Insider Premium to draft better contracts faster.